# US 2026/0060923 A1 · Oral thin film containing semaglutide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060923 A1
- Document ID: US20260060923A1
- Status: Published application
- Kind: A1
- Application number: 19/314,668
- Filed: 2025-08-29
- Published: 2026-03-05
- Earliest claimed: 2024-08-29
- Assignees: CURE Pharmaceutical Corporation
- Applicants: Cure Pharmaceutical, Inc.
- Inventors: Jose Bernardo; Robert Davidson
- Web page: https://patentgrep.com/patent/US20260060923A1

## CPC

- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 38/26: Glucagons
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An oral thin film (OTF) containing semaglutide, methods of manufacturing the same, and methods or orally administering the same.

## Claims

### Claim 1

An oral thin film (OTF) comprising:
semaglutide present in 2.6 wt. %;
water present in 8 wt. %;
carboxymethyl cellulose sodium present in 24.1 wt. %;
polyvinylpyrrolidone present in 13.8 wt. %;
cocoa butter present in 5.6 wt. %;
glycerin present in 15.5 wt. %;
polysorbate 80 present in 5.2 wt. %;
sucralose present in 3 wt. %;
microcrystalline cellulose present in 9 wt. %;
powder berry flavor present in 4.7 wt. %; and
liquid berry flavor present in 8.6 wt. %.

### Claim 2 (depends on 1)

The oral thin film (OTF) of claim 1, exhibiting≤10% strip-to-strip content variation and in vitro disintegration time<60 s.

### Claim 3 (depends on 1)

The oral thin film (OTF) of claim 1, that maintains>90% semaglutide content and complete disintegration after 24 months at 25° C./60% RH.

### Claim 4 (depends on 1)

The oral thin film (OTF) of claim 1, having tensile strength≥5 N/cm2, folding endurance≥300 cycles, and microbial limits as per USP <61>/<62> for oral dosage forms.

### Claim 5 (depends on 1)

A method comprising administering the oral thin film (OTF) of claim 1 to a subject.
